RESUMO
Adenocarcinoma of the small bowel is a rare tumor. The diagnosis is often tardy and surgical treatment is still palliative in most cases. A major interest toward this kind of tumor as well as an early diagnosis may give the opportunity to perform a radical operation allowing better results in terms of survival.
Assuntos
Adenocarcinoma/patologia , Neoplasias Intestinais/patologia , Intestino Delgado/patologia , Dor Abdominal/patologia , Dor Abdominal/cirurgia , Adenocarcinoma/cirurgia , Idoso , Idoso de 80 Anos ou mais , Emergências , Feminino , Humanos , Neoplasias Intestinais/cirurgia , Intestino Delgado/cirurgia , Metástase LinfáticaAssuntos
Colo/cirurgia , Reto/cirurgia , Adulto , Idoso , Infecções Bacterianas/prevenção & controle , Catárticos/uso terapêutico , Dieta , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/prevenção & controle , Cuidados Pré-Operatórios , Irrigação Terapêutica , Desequilíbrio Hidroeletrolítico/prevenção & controleRESUMO
Thirteen uraemic patients having undergone chronic haemodialysis from a minimum of 16 months to a maximum of 15 years (mean 6.5 years) with unsuitable peripheral vessels for standard arteriovenous fistulae, received Hemasite, a new vascular access device which provides vascular access without needle puncture. Eight devices are still being used routinely with enthusiastic acceptance by the patients. Three subjects died because of unrelated causes, two of whom had a functioning device. Nine thromboses occurred in five patients. Thrombectomy was successful in three subjects. There were two cases of infection with loss of one device. In conclusion, the main advantage of Hemasite is the possibility of performing haemodialysis without needles, thus potentially maintaining the longevity of graft fistula. The only disadvantage of the device is its cost.